Latest Breaking News On - Sobi media - Page 11 : comparemela.com

Sobi completes acquisition of CTI BioPharma Corp

Sobi completes acquisition of CTI BioPharma Corp
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCorporation law of the state delawareBiopharma corpCleopatra acquisition corpSobi investor relations teamCleopatra acquisitionGeneral corporation lawNorth americaMiddle eastSobi mediaOrphan biovitrum

Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor development was not detected during the study. .

United statesLydia abad franchInternational society on thrombosisSobi investor relations teamDevelopment of factorEuropean medicines agencyEuropean commissionHead of research developmentDrug administrationAnnual meetingMedical affairsChief medical officerBreakthrough therapyFast trackOrphan drugMedicines agency

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLydia abad franchDrug administrationEuropean medicines agencyMeeting of the international society on thrombosisSobi investor relations teamHead of research developmentDevelopment of factorEuropean commissionAnnual meetingInternational societyMedical affairsChief medical officerBreakthrough therapyFast trackOrphan drug

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

/PRNewswire/ Pivotal data from the Phase 3 XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein].

United statesLydia abad franchDrug administrationHead of research developmentDevelopment of factorMeeting of the international society on thrombosisEuropean commissionEuropean medicines agencySobi investor relations teamAnnual meetingInternational societyMedical affairsChief medical officerBreakthrough therapyFast trackOrphan drug

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLydia abad franchDrug administrationHead of research developmentDevelopment of factorEuropean commissionMeeting of the international society on thrombosisEuropean medicines agencySobi investor relations teamAnnual meetingInternational societyMedical affairsChief medical officerBreakthrough therapyFast trackOrphan drug